Biocure Technology Inc.
CUREX
CNSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -88.78% | -99.79% | -77.09% | -96.90% | -38.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -88.78% | -99.79% | -77.09% | -96.90% | -38.71% |
| Operating Income | 88.78% | 99.79% | 77.09% | 96.90% | 38.71% |
| Income Before Tax | -5.44% | 75.00% | 94.87% | 92.18% | -100.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.44% | 75.00% | 94.87% | 92.18% | -100.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.44% | 75.00% | 94.92% | 92.18% | -100.75% |
| EBIT | 88.78% | 99.79% | 77.09% | 96.90% | 38.71% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 7.14% | 76.47% | 96.31% | 91.67% | -100.80% |
| Normalized Basic EPS | 11.11% | 72.73% | 82.80% | 90.38% | 81.25% |
| EPS Diluted | 7.14% | 76.47% | 96.31% | 91.67% | -100.80% |
| Normalized Diluted EPS | 11.11% | 72.73% | 82.80% | 90.38% | 81.25% |
| Average Basic Shares Outstanding | 16.31% | 0.00% | 37.43% | -10.04% | -5.92% |
| Average Diluted Shares Outstanding | 16.31% | 0.00% | 37.43% | -10.04% | -5.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |